DermatologyNews.net

Dermatology Xagena

Results from two pivotal phase III studies evaluating the interleukin-17A ( IL-17A ) inhibitor Secukinumab ( AIN457 ) were published in the New England Journal of Medicine ( NEJM ). Secukinumab met ...


A meta-analysis has evaluated the efficacy and safety of Ustekinumab ( Stelara ) in the therapy of plaque psoriasis. The efficacy was estimated using relative risk of Psoriasis Area and Severity In ...


Certain acne treatments can, in rare instances, cause severe allergic reactions that are potentially life-threatening. The Food and Drug Administration ( FDA ) is warning that the use of certain acne ...


Bristol-Myers Squibb ( BMS ) has announced that a randomized blinded comparative phase 3 study evaluating Nivolumab versus Dacarbazine ( DTIC ) in patients with previously untreated BRAF wild-type adv ...


A man with almost no hair on his body has grown a full head of it after a novel treatment by clinicians at Yale University. There is currently no cure or long-term treatment for alopecia universalis, ...


Psoriasis is an inflammatory disorder, which has been reported to be associated with cardiovascular risks. Although increased cardiovascular risks in psoriasis are well established, there are no data ...


A post hoc analysis has examined the effects of Adalimumab ( Humira ) in patients with scalp and/or nail psoriasis from BELIEVE, a randomized, controlled, multicentre phase 3 safety and efficacy trial ...


New findings on Apremilast ( Otezla ), a selective inhibitor of phosphodiesterase 4 ( PDE4 ), from the ESTEEM 1 and 2 phase III studies in patients with moderate to severe plaque psoriasis were presen ...


Tofacitinib ( Xeljanz ) is a novel, oral Janus kinase inhibitor currently under investigation for plaque psoriasis. This exploratory analysis of a phase IIb, 12-week, dose-ranging study has evaluat ...


Vismodegib ( Erivedge ), a first-in-class Hedgehog pathway inhibitor, was Food and Drug Administration ( FDA ) approved for advanced basal cell carcinomas ( BCCs ) based on a single, nonrandomized, ph ...


OBSERVE-5 was a 5-year FDA-mandated surveillance registry of patients with psoriasis. Researchers have assessed long-term Etanercept ( Enbrel ) safety and effectiveness. Patients with moderate to s ...


Vismodegib ( Erivedge ), the first Food and Drug Administration ( FDA )-approved Hedgehog ( Hh ) signaling pathway inhibitor, in the treatment of advanced basal cell carcinoma ( BCC ). Activation o ...


A phase III study of the combination of Tafinlar ( Dabrafenib ) and Mekinist ( Trametinib ), compared to single agent therapy with Dabrafenib in patients with BRAF V600 E or K mutation positive unrese ...


Fungal skin infections, or dermatomycoses, are associated with a broad range of pathogens. Involvement of gram-positive bacteria is often suspected in dermatomycoses. Inflammation plays an important r ...


Apremilast ( Otezla ), a specific inhibitor of phosphodiesterase 4, modulates pro-inflammatory and anti-inflammatory cytokine production. Apremilast's effect on patient-reported outcomes ( PROs ) i ...